{"doi":"10.3389/fneur.2018.00483","title":"Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?","abstract":null,"journal":"Frontiers in Neurology","year":2018,"id":674359,"datarank":0.5289540786924243,"base_score":3.5263605246161616,"endowment":3.5263605246161616,"self_citation_contribution":0.5289540786924243,"citation_network_contribution":0.0,"self_endowment_contribution":0.5289540786924243,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":33,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1761927,"name":"Johanna Meyer-Wilmes","orcid":null,"position":1,"is_corresponding":false},{"id":1761928,"name":"Sonja Schönecker","orcid":null,"position":2,"is_corresponding":false},{"id":1761929,"name":"Jonas Schnabel","orcid":null,"position":3,"is_corresponding":false},{"id":1761930,"name":"Eva Brendel","orcid":null,"position":4,"is_corresponding":false},{"id":1384049,"name":"Catharina Prix","orcid":null,"position":5,"is_corresponding":false},{"id":1027922,"name":"Georg Nübling","orcid":"0000-0003-4492-7302","position":6,"is_corresponding":false},{"id":84308,"name":"Marcus Unterrainer","orcid":"0000-0002-8238-1198","position":7,"is_corresponding":false},{"id":84328,"name":"Nathalie L. Albert","orcid":"0000-0003-0953-7624","position":8,"is_corresponding":false},{"id":1224965,"name":"Oliver Pogarell","orcid":"0000-0001-6455-4190","position":9,"is_corresponding":false},{"id":7728,"name":"Robert Perneczky","orcid":"0000-0003-1981-7435","position":10,"is_corresponding":false},{"id":1761934,"name":"Cihan Catak","orcid":null,"position":11,"is_corresponding":false},{"id":550549,"name":"Katharina Bürger","orcid":"0000-0002-4091-2755","position":12,"is_corresponding":false},{"id":813073,"name":"Peter Bartenstein","orcid":"0009-0005-0734-4994","position":13,"is_corresponding":false},{"id":1761936,"name":"Kai Bötzel","orcid":null,"position":14,"is_corresponding":false},{"id":84330,"name":"Johannes Levin","orcid":"0000-0001-5092-4306","position":15,"is_corresponding":false},{"id":284703,"name":"Axel Rominger","orcid":"0000-0002-1954-736X","position":16,"is_corresponding":false},{"id":1388028,"name":"Matthias Brendel","orcid":"0000-0002-6522-4895","position":17,"is_corresponding":false},{"id":813065,"name":"Leonie Beyer","orcid":"0000-0002-7358-4495","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?","abstract":"Background: F-18-fluordeoxyglucose positron emission tomography (FDG-PET) is widely used for discriminative diagnosis of tau-positive atypical parkinsonian syndromes (T+APS). This approach now stands to be augmented with more specific tau tracers. Therefore, we retrospectively analyzed a large clinical routine dataset of FDG-PET images for evaluation of the strengths and limitations of stand-alone FDG-PET. Methods: A total of 117 patients (age 68.4 ± 11.1 y) underwent an FDG-PET exam. Patients were followed clinically for a minimum of one year and their final clinical diagnosis was recorded. FDG-PET was rated visually (positive/ negative) and categorized as high, moderate or low likelihood of T+APS and other neurodegenerative disorders. We then calculated positive and negative predictive values (PPV/ NPV) of FDG-PET readings for the different subgroups relative to their final clinical diagnosis. Results: Suspected diagnoses were confirmed by clinical follow-up (≥ 1 y) for 62 out of 117 (53%) of patients. PPV was excellent when FDG-PET indicated a high likelihood of T+APS in combination with low to moderate likelihood of another neurodegenerative disorder. PPV was distinctly lower when FDG-PET indicated only a moderate likelihood of T+APS or when there was deemed equal likelihood of other neurodegenerative disorder. NPV of FDG-PET with a low likelihood for T+APS was high. Conclusions: FDG-PET has high value in clinical routine evaluation of suspected T+APS, gaining satisfactory differential diagnosis in two thirds of the patients. One third of patients would potentially profit from further evaluation by more specific radioligands, with FDG-PET serving gatekeeper function for the more expensive methods.","is_dataset_classified":null,"base_score":3.5263605246161616,"endowment":3.5263605246161616,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"29973914","pmcid":"PMC6019471","openalex_id":"https://openalex.org/W2808890953","authors":[],"funders":[],"total_grants":0,"fwci":2.0196,"citation_percentile":0.85913079,"influential_citations":0,"citation_trend":[{"year":2019,"count":1},{"year":2020,"count":5},{"year":2021,"count":7},{"year":2022,"count":3},{"year":2023,"count":5},{"year":2024,"count":9},{"year":2025,"count":2},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.frontiersin.org/articles/10.3389/fneur.2018.00483/pdf","host_type":"journal"},{"url":"https://www.frontiersin.org/articles/10.3389/fneur.2018.00483/pdf","host_type":"publisher"},{"url":"https://www.frontiersin.org/article/10.3389/fneur.2018.00483/full","host_type":"publisher"},{"url":"https://doi.org/10.3389/fneur.2018.00483","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/29973914","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6019471","host_type":"repository"},{"url":"https://boris-portal.unibe.ch/handle/20.500.12422/63620","host_type":"repository"},{"url":"https://boris.unibe.ch/125647/","host_type":"repository"},{"url":"https://doaj.org/article/fd5955cc9a2c479e81d2f41f50e5943d","host_type":"repository"},{"url":"https://epub.ub.uni-muenchen.de/62942/","host_type":"journal"},{"url":"https://pub.dzne.de/search?p=id:%22DZNE-2020-06337%22","host_type":"repository"},{"url":"http://hdl.handle.net/10044/1/61041","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC6019471","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC6019471?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Parkinson's Disease Mechanisms and Treatments","Neurological disorders and treatments","Alzheimer's disease research and treatments"],"mesh_terms":[],"keywords":["Progressive supranuclear palsy","Corticobasal degeneration","Pet imaging","Medicine","Nuclear medicine","Positron emission tomography","Radiology","Pathology","Disease","PET","Atypical Parkinsonian Syndrome","Clinical Routine","F-18-fdg"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Reduced inequalities"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-16T16:35:38.578647Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}